Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsy

NCT06377930 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Focal Onset Seizures

Interventions

DRUG: RAP-219

Sponsor

Rapport Therapeutics Inc.